<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064165</url>
  </required_header>
  <id_info>
    <org_study_id>HIP/FUSION#2</org_study_id>
    <nct_id>NCT03064165</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade</brief_title>
  <official_title>Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elective Surgery Centre, Silkeborg Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of an obturator nerve block on the postoperative pain and
      opioid consumption after total hip replacement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid dose 0-12 hour after total hip replacement</measure>
    <time_frame>0-12 hour after completion of total hip replacement</time_frame>
    <description>Cumulated dose of opioid 0-12 hour after total hip replacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulated dose of opioid 12-18 hours after total hip replacement.</measure>
    <time_frame>12-18 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest at time of examination (numeric rating scale)</measure>
    <time_frame>1, 2, 5, 7 and 24 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at passive 90-degree hip flexion (numeric rating scale)</measure>
    <time_frame>1, 2, 5, 7 and 24 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst pain during ambulation on the day of surgery</measure>
    <time_frame>5 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from completion of surgery to first dose of opioid</measure>
    <time_frame>24 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of nausea on time of examination (numeric rating scale)</measure>
    <time_frame>1, 2, 5, 7 and 24 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of emesis 0-18 hours after total hip replacement.</measure>
    <time_frame>0-18 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated dose of ondansetron 0-18 hours after total hip replacement</measure>
    <time_frame>0-18 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated dose of droperidol 0-18 hours after total hip replacement</measure>
    <time_frame>0-18 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay on post anesthesia care unit after completion of total hip replacement</measure>
    <time_frame>24 hours after completion of total hip replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay on hospital after completion of total hip replacement</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to ambulate 5 hours after surgery</measure>
    <time_frame>5 hours after completion of total hip replacement</time_frame>
    <description>Ability to sit, stand, walk with tall rollator and walk with crutches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor control with operated leg</measure>
    <time_frame>5 hours after completion of total hip replacement</time_frame>
    <description>Physiotherapist evaluating motor control with operated leg during ambulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported sleep quality the first night after total hip replacement</measure>
    <time_frame>24 hours after completion of total hip replacement</time_frame>
    <description>Self-reported sleep quality on a 3-point-scale: 2 = Undisturbed sleep; 1 = Sleep disturbed by other reasons than pain; 0 = Sleep disturbed by pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of spinal anesthesia</measure>
    <time_frame>0-4 hours after completion of total hip replacement</time_frame>
    <description>Time from end of operation until regain of normal sensibility on anterior femur.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obturator Nerve Block</condition>
  <condition>Total Hip Replacement</condition>
  <arm_group>
    <arm_group_label>Obturator nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham block</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Postoperative sham-block with normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine-epinephrine</intervention_name>
    <description>Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.</description>
    <arm_group_label>Obturator nerve block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham block</intervention_name>
    <description>Injection as for obturator nerve block, but with placebo</description>
    <arm_group_label>Sham block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Obturator nerve block</intervention_name>
    <description>Postoperative obturator nerve block</description>
    <arm_group_label>Obturator nerve block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 9mg/mL</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Sham block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for primary hip replacement in spinal anesthesia

          -  Age &gt;= 18 years

          -  American Society of Anesthesiologists physical status classification score I-III

          -  Informed consent

        Exclusion Criteria:

          -  Lacking the ability to corporate

          -  Lacking the ability to speak danish

          -  Planned discharge on the same day of surgery

          -  Neuropathy of the lower extremities

          -  Contraindications for NonSteroidal Anti-Inflammatory Drugs (NSAID)

          -  Contraindications for dexamethasone

          -  Chronic opioid demanding pain

          -  Pregnancy

          -  Allergy towards one or both investigatory medicinal products

          -  Active treatment with amiodarone

          -  Active treatment with verapamil

          -  Active treatment with corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Niels D Nielsen, MD</last_name>
    <phone>+4522838334</phone>
    <email>nielsdn@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elective Surgery Centre</name>
      <address>
        <city>Silkeborg</city>
        <zip>DK-8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels D Nielsen, MD</last_name>
      <phone>+4522838334</phone>
      <email>nielsdn@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Niels D Nielsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Niels Dalsgaard Nielsen</investigator_full_name>
    <investigator_title>MD, PhD-fellow</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared through the Danish Data Archive.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

